Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data

Megan Jagosky, Antoinette R Tan Department of Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USACorrespondence: Antoinette R TanLevine Cancer Institute, Atrium Health, 1021 Morehead Medical Drive, Charlotte, NC, 28204, USATel +1 980-442-...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jagosky M, Tan AR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	breast cancer her2 trastuzumab pertuzumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0fcf1db141b64385b45d0407d409ea8d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0fcf1db141b64385b45d0407d409ea8d
record_format	dspace
spelling	oai:doaj.org-article:0fcf1db141b64385b45d0407d409ea8d2021-12-02T17:43:14ZCombination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data1179-1314https://doaj.org/article/0fcf1db141b64385b45d0407d409ea8d2021-06-01T00:00:00Zhttps://www.dovepress.com/combination-of-pertuzumab-and-trastuzumab-in-the-treatment-of-her2-pos-peer-reviewed-fulltext-article-BCTThttps://doaj.org/toc/1179-1314Megan Jagosky, Antoinette R Tan Department of Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USACorrespondence: Antoinette R TanLevine Cancer Institute, Atrium Health, 1021 Morehead Medical Drive, Charlotte, NC, 28204, USATel +1 980-442-6400Fax +1 980-442-6321Email Antoinette.Tan@atriumhealth.orgAbstract: Human epidermal growth factor receptor type 2 (HER2) is a relevant and effective target in breast cancer. The development of monoclonal antibodies against HER2 has revolutionized the treatment of HER2-positive breast cancer. The humanized monoclonal antibody, trastuzumab, was the first in its class to be widely adopted. It was initially studied in the metastatic setting and then in the treatment of early-stage disease, demonstrating significant improvement in overall survival in both settings. The addition of pertuzumab further improved upon results achieved with trastuzumab and chemotherapy, specifically extending overall survival in patients with metastatic disease, lessening the risk of recurrence when used in the adjuvant setting, and improving pathologic complete response rate when utilized in the neoadjuvant setting. In this article, we review the studies that support the use of HER2-directed monoclonal antibodies in early-stage breast cancer both in the adjuvant and neoadjuvant settings and focus on the success of dual HER2-targeted therapy achieved with the combination of trastuzumab and pertuzumab. A newer way to administer these agents, specifically the subcutaneous formulation of pertuzumab and trastuzumab with recombinant human hyaluronidase, will also be discussed.Keywords: breast cancer, HER2, trastuzumab, pertuzumabJagosky MTan ARDove Medical Pressarticlebreast cancerher2trastuzumabpertuzumabNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 13, Pp 393-407 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer her2 trastuzumab pertuzumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	breast cancer her2 trastuzumab pertuzumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jagosky M Tan AR Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
description	Megan Jagosky, Antoinette R Tan Department of Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USACorrespondence: Antoinette R TanLevine Cancer Institute, Atrium Health, 1021 Morehead Medical Drive, Charlotte, NC, 28204, USATel +1 980-442-6400Fax +1 980-442-6321Email Antoinette.Tan@atriumhealth.orgAbstract: Human epidermal growth factor receptor type 2 (HER2) is a relevant and effective target in breast cancer. The development of monoclonal antibodies against HER2 has revolutionized the treatment of HER2-positive breast cancer. The humanized monoclonal antibody, trastuzumab, was the first in its class to be widely adopted. It was initially studied in the metastatic setting and then in the treatment of early-stage disease, demonstrating significant improvement in overall survival in both settings. The addition of pertuzumab further improved upon results achieved with trastuzumab and chemotherapy, specifically extending overall survival in patients with metastatic disease, lessening the risk of recurrence when used in the adjuvant setting, and improving pathologic complete response rate when utilized in the neoadjuvant setting. In this article, we review the studies that support the use of HER2-directed monoclonal antibodies in early-stage breast cancer both in the adjuvant and neoadjuvant settings and focus on the success of dual HER2-targeted therapy achieved with the combination of trastuzumab and pertuzumab. A newer way to administer these agents, specifically the subcutaneous formulation of pertuzumab and trastuzumab with recombinant human hyaluronidase, will also be discussed.Keywords: breast cancer, HER2, trastuzumab, pertuzumab
format	article
author	Jagosky M Tan AR
author_facet	Jagosky M Tan AR
author_sort	Jagosky M
title	Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
title_short	Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
title_full	Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
title_fullStr	Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
title_full_unstemmed	Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
title_sort	combination of pertuzumab and trastuzumab in the treatment of her2-positive early breast cancer: a review of the emerging clinical data
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/0fcf1db141b64385b45d0407d409ea8d
work_keys_str_mv	AT jagoskym combinationofpertuzumabandtrastuzumabinthetreatmentofher2positiveearlybreastcancerareviewoftheemergingclinicaldata AT tanar combinationofpertuzumabandtrastuzumabinthetreatmentofher2positiveearlybreastcancerareviewoftheemergingclinicaldata
_version_	1718379629008388096

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data

Ejemplares similares